共 37 条
Biomimetic tolerogenic artificial antigen presenting cells for regulatory T cell induction
被引:19
作者:
Rhodes, Kelly R.
[1
,2
,3
]
Meyer, Randall A.
[1
,2
,3
]
Wang, Justin
[1
,2
,3
]
Tzeng, Stephany Y.
[1
,2
,3
]
Green, Jordan J.
[1
,2
,3
,4
,5
,6
,7
,8
]
机构:
[1] Johns Hopkins Univ, Dept Biomed Engn, Sch Med, 400 N Broadway,Smith Bldg Room 5017, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Translat Tissue Engn Ctr, Sch Med, Baltimore, MD 21231 USA
[3] Johns Hopkins Univ, Inst NanoBioTechnol, Sch Med, Baltimore, MD 21231 USA
[4] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21231 USA
[5] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21231 USA
[6] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21231 USA
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Sch Med, Baltimore, MD 21231 USA
[8] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Sch Med, Baltimore, MD 21231 USA
基金:
美国国家卫生研究院;
美国国家科学基金会;
关键词:
Artificial antigen presenting cell;
Immunotherapy;
Regulatory T cell;
Tolerance;
Bioengineering;
Immunoengineering;
TGF-BETA;
EPIGENETIC CONTROL;
FOXP3;
EXPRESSION;
IL-2;
CD39;
CD73;
ACTIVATION;
TOLERANCE;
EXPANSION;
DELIVERY;
D O I:
10.1016/j.actbio.2020.06.004
中图分类号:
R318 [生物医学工程];
学科分类号:
0831 ;
摘要:
Regulatory T cell (Treg)-based therapeutics are receiving increased attention for their potential to treat autoimmune disease and prevent transplant rejection. Adoptively transferred Tregs have shown promise in early clinical trials, but cell-based therapies are expensive and complex to implement, and "off-the-shelf" alternatives are needed. Here, we investigate the potential of artificial antigen presenting cells (aAPCs) fabricated from a blend of negatively charged biodegradable polymer (poly(lactic-co-glycolic acid), PLGA) and cationic biodegradable polymer (poly(beta-amino ester), PBAE) with incorporation of extracellular protein signals 1 and 2 and a soluble released signal 3 to convert naive T cells to induced Foxp3+ Treg-like suppressor cells (iTregs) both in vitro and in vivo in a biomimetic manner. The addition of PBAE to the aAPC core increased the conjugation efficiency of signal proteins to the particle surface and resulted in enhanced ability to bind to naive T cells and induce iTregs with potent suppressive function. Furthermore, PLGA/PBAE tolerogenic aAPCs (TolAPCs) supported the loading and sustained release of signal 3 cytokine TGF-beta. A single dose of TolAPCs administered intravenously to C57BL/6 J mice resulted in an increased percentage of Foxp3+ cells in the lymph nodes. Thus, PLGA/PBAE TolAPCs show potential as an "off-the-shelf" biomimetic material for tolerance induction. Statement of Significance Regulatory T cells (Tregs) are promising for basic research and translational medicine as they can induce tolerance and have the potential to treat autoimmune diseases such as type 1 diabetes and multiple sclerosis. As cell-based therapies are expensive and difficult to manufacture and implement, non-cellular methods of engineering endogenous Tregs are needed. The research reported here describes a new type of biomimetic particle, tolerogenic artificial antigen presenting cells (TolAPCs) fabricated from a blend of negatively charged biodegradable polymer, poly(lactic-co-glycolic acid), and positively charged biodegradable polymer, poly(beta-amino ester), along with key biomolecular signals: extracellularly presented protein signals 1 and 2 and a soluble released signal 3. These TolAPCs bind to naive T cells and induce Foxp3+ Treg-like suppressor cells with potent suppressive function. In both in vitro and in vivo studies, it is shown that this non-cellular approach is useful to induce tolerance. (c) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:136 / 148
页数:13
相关论文